key: cord-0030455-b9u4dum1
authors: Lähteenmäki, Hanna; Tervahartiala, Taina; Räisänen, Ismo T.; Pärnänen, Pirjo; Mauramo, Matti; Gupta, Shipra; Sampson, Victoria; Rathnayake, Nilminie; Heikkinen, Anna‐Maria; Alassiri, Saeed; Gieselmann, Dirk‐Rolf; Frankenberger, Roland; Sorsa, Timo
title: Active MMP‐8 point‐of‐care (PoC)/chairside enzyme‐test as an adjunctive tool for early and real‐time diagnosis of peri‐implantitis
date: 2022-02-03
journal: Clin Exp Dent Res
DOI: 10.1002/cre2.537
sha: 895b65bb195faef542307d883b805494fe2e2deb
doc_id: 30455
cord_uid: b9u4dum1

OBJECTIVE: The aim of this study was to investigate the utility of the active matrix metalloproteinase (aMMP‐8)‐point‐of‐care (PoC) test as a quantitative real‐time chair‐side diagnostic tool for peri‐implant diagnosis, as well as assess the potentially developing and ongoing risk relative to the traditional clinical methods. BACKGROUND: Current peri‐implant and periodontal disease diagnoses rely on clinical and radiological examinations. This case‐control study investigated the applicability of aMMP‐8‐PoC immunotest for quantitative real‐time diagnosis and monitoring of dental implants in health and disease. METHODS: Sixty‐eight patients visiting a specialist clinic for maintenance following dental implant placement underwent assessment of their peri‐implant health. aMMP‐8‐PoC peri‐implant sulcular fluid (PISF) lateral‐flow immunotests were performed using ImplantSafe® technology quantitated by ORALyzer®. In addition, the PISF samples were analyzed for total MMP‐8, calprotectin, and interleukin (IL)‐6 by enzyme‐linked immunosorbent assays (ELISA), aMMP‐8 by western immunoblot, and MMP‐2 and MMP‐9 by gelatin zymography. RESULTS: The aMMP‐8‐PoC test promptly recorded and reflected peri‐implant disease, differentiating it clearly from health. X‐ray findings (bone loss > 2 mm), peri‐implant pocket depth ≥ 3 mm, and bleeding on probing were significantly more prevalent among implants positive for the aMMP‐8‐PoC test. aMMP‐8/ORALyzer analysis was more precise in recording disease than total MMP‐8, calprotectin, IL‐6, MMP‐2, and MMP‐9. CONCLUSIONS: The aMMP‐8‐PoC test can be conveniently implemented to alert for and detect active collagenolysis affecting peri‐implant tissues, both in the early and advanced stages of the disease. Active and fragmented MMP‐8 exhibits a strong and significant association with peri‐implantitis as compared to total MMP‐8 and other biomarkers and can be utilized as the POC/chairside biomarker of choice in the new classification of peri‐implantitis.

The popularity of dental implants as a treatment option for replacing missing teeth has substantially increased over the past 20 years (Elani et al., 2018) . This development poses a challenge to oral health professionals because although in many cases dental implant treatments have been successful having a high survival rate, implant complications and failures have been frequent (Pjetursson et al., 2012) . Peri-implantitis, a pathological inflammatory condition around dental implants, is a major risk factor for late dental implant failures (Manor et al., 2009; Schwarz et al., 2018) . Previous studies have estimated that the prevalence of peri-implantitis may be as high as 23% of dental implants, while peri-implant mucositis, which is considered a precursor for peri-implantitis, may affect more than 40% of implants (Derks & Tomasi, 2015; Heitz-Mayfield & Salvi, 2018) .

Current peri-implant and periodontal disease diagnosis rely on clinical and radiological examinations, which have been commonly used by all oral health professionals for decades and are easy and practical to interpret. However, clinicians are only able to detect and measure peri-implant/periodontal diseases after clinical manifestations have occurred using the traditional methods. To overcome this limitation, biomarkers have been studied extensively (Alassy et al., 2019; Arias-Bujanda et al., 2019; Carinci et al., 2019; Gul et al., 2020) . Key biomarkers of peri-implant and periodontal tissue destruction, once identified, could alert the clinician as to the onset of collagen breakdown, long before clinical manifestations set in. In adjunct with the traditional methods, they could increase the accuracy of early detection of peri-implant and periodontal diseases, prediction of disease progression, and monitoring of treatment effects (Gul et al., 2020) .

Periodontal and peri-implant connective tissue consists mainly of Type I collagen. Results from previous studies support the concept of matrix metalloproteinase-8 (MMP-8), also known as neutrophil collagenase or collagenase-2, as a potential key biomarker responsible for connective tissue destruction or active degeneration of periodontal and peri-implant disease (Alassy et al., 2019; Al-Majid et al., 2018; Arias-Bujanda et al., 2019; Carinci et al., 2019; Gul et al., 2020; Sorsa et al., 2016) . MMP-8 is a major host-derived collagenolytic proteinase and is regarded as primarily responsible for the irreversible destruction of periodontal and peri-implant tissues (Buduneli, 2020; Gul et al., 2020; Sorsa et al., 2006) . MMP-8 is responsible for the disintegration and processing of collagens and bioactive inflammatory nonmatrix mediators, not only in various inflammatory and malignant tissue destructive diseases but also in wound healing, immune response and tissue remodeling (Buduneli, 2020; Dejonckheere et al., 2011) . It can break down almost all the proteinaceous structural components of connective tissues and basement membranes, as well as process distinct bioactive nonmatrix inflammatory immune mediators. It can also act in a degradative manner upon serpins and insulin receptors (Lauhio et al., 2016; Sorsa et al., 1993) .

MMPs, such as MMP-8, are secreted from the cell as latent pro-MMPs (Nagase, 1997) . The presence of a proteinase susceptible "bait" region in the propeptide allows reactive oxygen species, tissue and plasma proteinases, or opportunistic microbial proteinases (alone or in concert) to activate pro-MMPs. Once activated, the catalytically competent MMP, such as active MMP-8 (aMMP-8), acts as a potential initiator of interstitial collagenolysis at inflammatory sites. It is the pathologically elevated concentration of active MMP-8 and not the total or latent form, which has been demonstrated to distinguish healthy tissue from gingivitis, periodontitis, peri-implant mucositis, pre-implantitis, and peri-implantitis (Kiili et al., 2002; Lähteenmäki et al., 2020; Lee et al., 1995; Ma et al., 2000; Mancini et al., 1999; Romanelli et al., 1999; Romero-Castro et al., 2020; Sorsa, Alassiri, et al., 2020; Sorsa, Bacigalupo, et al., 2020; Sorsa et al., 2006 Sorsa et al., , 2010 Sorsa et al., , 2016 Verhulst et al., 2019; Wang et al., 2016; Wohlfahrt et al., 2014) . In healthy periodontal and peri-implant tissues, the concentration of the active form of MMP-8 is significantly lower or absent altogether, indicating a healthy status, compared to more severe inflammatory diseased conditions in these tissues (Gangbar et al., 1990; Golub et al., 2020; Keles Yucel et al., 2020; Lee et al., 1995; Mancini et al., 1999; Räisänen et al., 2018; Romanelli et al., 1999; Sorsa, Bacigalupo, et al., 2020; Sorsa et al., 2006; Teronen et al., 1997; Xu et al., 2008) .

The aMMP-8 enzyme, unlike total MMP-8, shows consistent and sustained pathological elevation that can be assessed from the pocket/peri-implant pocket fluid and mouthwash by aMMP-8 analysis Gangbar et al., 1990; Golub et al., 2020; Izadi Borujeni et al., 2015; Lee et al., 1995; Lorenz et al., 2017; Mancini et al., 1999; Öztürk et al., 2021; Romanelli et al., 1999; Schmalz et al., 2019; Sorsa, Alassiri, et al., 2020) .

The aim of this study was to investigate the utility of the aMMP-8-PoC/chairside enzyme (ImplantSafe/ORALyzer ® )-test as a quantitative real-time chair-side diagnostic tool for peri-implant diagnosis, as well as assess the potentially developing and ongoing risk relative to the traditional clinical methods. Furthermore, the diseased and healthy peri-implant sulcular fluid (PISF) samples were analyzed by independent immunoassays, for total MMP-8, calprotectin, and interleukin (IL)-6 by enzyme-linked immunosorbent assays (ELI-SA) analysis and additionally by western immunoblotting for MMP-8, and MMP-2 and MMP-9 were evaluated by utilizing gelatinzymography to compare them with the aMMP-8-PoC/chairside test. from July 2019 to January 2020. Patients who were males or females, smokers or nonsmokers, at least 45 years of age, and who had one or more dental implants were included in this study. If the patient had more than one dental implant, only one implant was randomly chosen and an aMMP-8 PoC test was performed in the buccal sulcus of that implant. Patients who had used anti-inflammatory medication and/or antibiotics or had received peri-implant treatment within the last 6 months were excluded from this study. Dental implants (Nobel Biocare ® implants) had been surgically placed according to routine surgical procedures by an experienced dental implant specialist and maintenance therapy was advised at a gap of 6-12 months following implant placement. The surface types of dental implants placed varied between crowns and bridge structures. At the maintenance visit, oral fluid samples were collected and oral examination including bleeding on probing (BOP) was performed and pocket depths at six sites per implant (disto-buccal, mid-buccal, mesio-buccal, distopalatal, mid-palatal, mesio-palatal) were recorded using a standard millimeter probe (Hu-Friedy Manufacturing Co., LLC). An X-ray of the implant area was also taken to assess alveolar bone destruction. Finally, maintenance therapy was provided at the end of the visit following the Swedish National Guidelines (https://www. socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/ nationella-riktlinjer/2011-5-1.pdf). The treatment effect of antiinfective treatment on peri-implantitis was measured after 4-6 weeks after baseline by the aMMP-8 PoC test.

Previous studies demonstrate a large effect size for site-specific aMMP-8 measurements by immunofluorometric assay (IFMA) and

POCT utilizing the same monoclonal antibodies in peri-implantitis diagnostics Golub et al., 2020; Lähteenmäki et al., 2020; Rathnayake et al., 2017; Sorsa, Bacigalupo, et al., 2020) .

Based on these studies, a minimum of 26 participants per group was calculated to identify the differences between healthy and peri-implantitis groups with α = .05 and power = 0.80. Two groups were enrolled: subjects with peri-implantitis (n = 26) and healthy subjects (n = 42). Peri-implantitis was defined as having the combination of X-ray findings (bone loss > 2 mm), BOP, and peri-implant pockets of ≥3 mm around the dental implant, while healthy controls were defined as the absence of these three clinical measurements and parameters. Clinical peri-implant measurements were performed by a trained and calibrated dental hygienist (H. L.). 

The molecular forms of MMP-8 were detected by a modified enhanced chemiluminescence Western blot analysis kit according to the protocol recommended by the manufacturer (GE Healthcare) and described by Gürsoy et al. (2018) and Hanemaaijer et al. (1997) .

Briefly, the PISF samples were mixed with Laemmli sample buffer without any reducing reagents and heated for 5 min, followed by protein separation with 11% sodium dodecyl sulfate (SDS)polyacrylamide gels with prestained low range molecular weight so- anti-MMP-8, and a horseradish peroxidase-linked secondary antibody (GE Healthcare). The immunoblots were quantified by GS-700

Imaging Densitometer Scanner (Bio-Rad) using the Quantity One program (Bio-Rad).

The gelatinolytic activity was assayed from PISF samples with zymographic technique, using 11% SDS-polyacrylamide gels im- 

General patient characteristics were summarized for study patients, those with dental peri-implantitis, and healthy controls. The differences between peri-implantitis and healthy controls were compared Diagnostic accuracy of the biomarker candidates to discriminate periimplantitis from a healthy implant was studied by receiver operating characteristic (ROC) analysis and the area under the ROC curve (AUC).

This was carried out using each biomarker and its adjusted logistic regression model (adjusted for gender, age of dental implant, and smoking). The Youden index was used to define the optimal cut-offs from the ROC curves for each biomarker (unadjusted and adjusted models). Diagnostic sensitivity (Se), specificity (Sp), the percentage of false negatives (FN) and false positives (FP), test accuracy (Acc), and Matthews correlation coefficient (MCC) were calculated for each biomarker by using the cut-off to assess the quality of classification.

There were two patients with peri-implantitis and four with a healthy implant that had missing values in the age of dental implant.

Thus, the total sample size for unadjusted calculations was 68, and that for adjusted calculations, 62. 3 | RESULTS

Sixty-eight adults with dental implants were assessed. There were 26 males and 42 females, and their ages ranged from 51 to 92 years.

No significant differences were found between peri-implantitis and healthy groups in patients' age, gender, smoking habits, or systemic diseases. Age of dental implant was significantly higher (mean difference 1.46 years) in the peri-implantitis group (p = .030). The demographic characteristics of the peri-implantitis patients and their healthy controls are shown in Table 1 .

Analysis of biomarker levels in PISF was performed for aMMP-8, total MMP-8, calprotectin, and IL-6 to assess their potential association with peri-implantitis ( Table 2) . Levels of all biomarkers were higher in dental implants with peri-implantitis than in healthy controls The aMMP-8-PoC test assay was a strong positive (163.83 ng/ml).

ROC analysis for the studied biomarkers and their discriminatory ability to classify peri-implantitis and health is presented in Table 3 and Optimal cut-off points to classify healthy and peri-implantitis implants were defined for each biomarker (unadjusted and adjusted for gender, age of dental implant and smoking) by using Youden's index ( 3.4 | MMP-8, MMP-2, and MMP-9 species versus peri-implant health and peri-implantitis 

In this study, we observed a significant association between the aMMP-8-PoC/chairside enzyme test results and the prevalence of peri-implantitis and clinical peri-implant risk factors. We found that peri-implant tissue damage involving active collagenolysis, indicated by the elevated aMMP-8 levels, was significantly more common in | 489 dental implants that had peri-implantitis compared with healthy implants. Furthermore, low aMMP-8 levels (<20 ng/ml) in PISF were clearly linked to healthy implant defined as the absence of the combination of X-ray findings (bone loss > 2 mm), BOP, and periimplant pockets of ≥3 mm around the dental implant. On the other hand, the increase in aMMP-8 levels was associated with the combination of these three clinical measurements and parameters (periimplantitis): moderate aMMP-8 levels (≥20 ng/ml) indicated the elevated risk of peri-implantitis and high aMMP-8 levels (≥80 ng/ml) indicated an even higher risk for the three clinical peri-implantitis parameters that may suggest a more rapid disease progression. This was also confirmed with western immunoblot analysis utilizing an independent polyclonal and specific MMP-8 antibody demonstrating the elevation of activated and fragmented MMP-8 species in the diseased PISF, but not in the healthy PISF that contained only latent MMP-8 species. These findings support and further extend previous T A B L E 2 Levels of biomarkers among healthy dental implants or with peri-implantitis (n = 68) F I G U R E 1 (a) Boxplots of biomarker concentrations per healthy implant and peri-implantitis groups; (b) quantitative versus visual active matrix metalloproteinase (aMMP)-8 point-of-care test and estimates of cut-offs for peri-implant health and peri-implantitis maximizing the agreement between the two aMMP-8 tests (n = 68) studies that have shown not only the direct role of collagenase activity (active MMP-8, not latent/total MMP-8) in the progression of attachment loss, (Kiili et al., 2002; Lee et al., 1995; Mancini et al., 1999; Romanelli et al., 1999; Sorsa et al., 2006) but also aMMP-8 levels in oral fluids correlating well with clinical periodontal/peri-implant parameters in adults and adolescents Izadi Borujeni et al., 2015; Lähteenmäki et al., 2020; Lee et al., 1995; Lorenz et al., 2017; Räisänen et al., 2019; Schmalz et al., 2019; Sorsa, Alassiri, et al., 2020; Sorsa, Bacigalupo, et al., 2020; Xu et al., 2008) . Furthermore, previous studies indicate that microbial burden could act as an up-regulator in the aMMP-8 cascade (proteolytic activation of pro-MMP-8 to aMMP-8) (Gürsoy et al., 2018; Nieminen et al., 2018; Sorsa et al., 1992 Sorsa et al., , 1995 . The onset of disease is, hence, heralded by the elevation of periodontal/ peri-implant tissue destruction associated biomarkers, indicating collagenolysis.

We extended our analysis to compare the aMMP-8-PoC test assay measuring aMMP-8 and its levels with other potential biomarkers (total MMP-8, calprotectin, and IL-6 ELISAs). Although their levels, in addition to aMMP-8, were elevated in periimplantitis compared with healthy implants, aMMP-8 had the best diagnostic accuracy to discriminate peri-implant health and disease as judged from ROC-analysis. This supports and further extends our prior studies that have shown that aMMP-8 measured by the aMMP-8-PoC test assay is seemingly superior to other tested potential biomarkers, including neutrophil elastase, calprotectin, tissue inhibitor of MMPs (TIMP)-1, myeloperoxidase, BOP, and MMP-9 in classifying dental implants as healthy or diseased (Golub et al., 2020; Lähteenmäki et al., 2020; Sorsa, Bacigalupo, et al., 2020) . Moreover, we found that successful peri-implantitis treatment converted the elevated (≥20 ng/ml) aMMP-8 levels in the PISF samples to low/healthy (<20 ng/ml) aMMP-8 levels in PISF. Thus, our results support previous studies that have shown that the aMMP-8 levels can be used to monitor and assess periodontal/peri-implant treatment success and failure (Alassiri Golub et al., 2020; Lähteenmäki et al., 2020; Leppilahti et al., , 2015 Sorsa, Bacigalupo, et al., 2020; Thierbach et al., 2016) However, the definition of healthy dental implant and peri-implantitis has eventually an impact on the balance between sensitivity and specificity and should be considered when comparing the results in this study with other studies. There is quite a variation in the case definitions of peri-implantitis in the literature, yet the main criteria for peri-implantitis in most of the studies have been based on BOP, PD ≥ 3 mm, and cases of crestal bone loss of ≥2 mm (Natto et al., 2019; Renvert et al., 2018) . And in periimplant health, PD should in general be ≤5 mm . Thus, the definition used in this study is in line with what has been considered peri-implantitis in the literature. The rational and the reason for more strict definition regarding PD in this study was to make sure that the dental implants that were defined healthy (in terms of clinical signs) would really be healthy.

To ensure long-term periodontal/peri-implant health, it is imperative to maintain collagen stability and integrity. As discussed earlier, traditional tools like dental probes, X-rays, or clinical examination by inspection are unable to reliably detect active collagenolysis or the pivotal point between health and disease.

Analyzing oral fluids for aMMP-8 levels offers a noninvasive and nonbacteremic method to make the invisible process of collagenolysis visible (Gul et al., 2020) . Based on the result of the aMMP-8 analysis, it is possible to evaluate the current state and disease activity of the periodontal/peri-implant tissues and thus conveniently assess the risk of both developing and ongoing collagen degradation/collagenolysis, to predict possible future attachment tissue loss (Gul et al., 2020; Lee et al., 1995; Leppilahti et al., , 2015 . In other words, the beauty of the aMMP-8

POCT for clinicians is its ability to alarm collagenolytic tissue de- Izadi Borujeni et al., 2015; Kiili et al., 2002; Lähteenmäki et al., 2020; Lee et al., 1995; Lorenz et al., 2017; Mancini et al., 1999; Räisänen et al., 2019 Romanelli et al., 1999; Schmalz et al., 2019; Sorsa, Alassiri, et al., 2020; Sorsa, Bacigalupo, et al., 2020; Sorsa et al., 2006; Xu et al., 2008) . Currently, there is no gold standard for disease activity and real-time progression of the disease. Thus, biomarker studies, like the present one, are forced to compare the measurements against the current clinical diagnostic parameters even if not necessarily perfectly accurate.

The 2018 classification system of periodontitis has the necessary framework to implement biomarkers (Tonetti et al., 2018) .

Similarly, biomarkers could be considered to be integrated for the assessment of peri-implant in the official classification system of peri-implant diseases (Berglundh et al., 2018) . Recent studies regarding periodontitis as described by the new classification system of periodontitis have presented promising results of the use of aMMP-8 as an adjunctive diagnostic tool to traditional clinical methods (Chaparro et al., 2020; Keles Yucel et al., 2020; Öztürk et al., 2021; Sorsa, Alassiri, et al., 2020) . Furthermore, the present study and our previous studies indicate similarly that aMMP-8 is a potential candidate to act as a biomarker in the disease F I G U R E 3 Receiver operating characteristic (ROC) analysis illustrating the diagnostic ability of the biomarker candidates to discriminate healthy implant from peri-implantitis: (a) unadjusted (n = 68) and (b) adjusted for gender, age of dental implant and smoking (n = 62) classification for peri-implantitis Golub et al., 2020; Lähteenmäki et al., 2020; Sorsa, Bacigalupo, et al., 2020; Thierbach et al., 2016) . In addition to these diseases, elevated aMMP-8 concentrations in oral fluids are associated with (pre)diabetes and gestational diabetes, and the aMMP-8-PoC enzyme test can also identify the risk of diabetes (and eventually

other serious systemic diseases) as well as the destructive oral side-effects of radiotherapy for head and neck cancer (Chaparro et al., 2020; Grigoriadis et al., 2019 Grigoriadis et al., , 2021 Keskin et al., 2020; . Overall, aMMP-8 has the potential to influence and improve not only the diagnostics of periodontal and peri-implant diseases but also the interdisciplinary collaboration between dental and healthcare professionals in their pursuit of attaining good oral and general health for their patients .

aMMP-8-PoC/chairside test can be conveniently implemented to alert for and detect active collagenolysis affecting peri-implant tissues, both in the early and advanced stages of the disease. Active and fragmented MMP-8 exhibits a strong and significant association with peri-implantitis as compared to total MMP-8 and other biomarkers.

The data demonstrate that an aMMP-8 chairside assay can be used as a convenient and reliable adjunctive tool in the diagnosis and monitoring of peri-implantitis. These results need to be clarified in further studies.

This study was funded by the Helsinki and Uusimaa Hospital District Gelatin-zymographic analysis of peri-implantitis (Lanes 1-6) and healthy (Lanes 7-12) PISF; Lane 13 represents positive control of neutrophil gelatinase B. Observe similar forms and levels of MMP-9 but hardly not at all MMP-2 (in the 62-72 kDa areas) in both peri-implantitis and healthy PISF. Here, pMMP-9 and aMMP-9 indicate pro-and active species, respectively. Mobilities of the molecular weight markers are indicated on the left (Panels a and b). (c) The effect of treatments of peri-implantitis on aMMP-8 PoC/chair-side PISF visual test outcomes (+ and −, n = 6) before (Lanes 1-6) and 4-6 weeks after (Lanes 7-12) treatments. Two lines indicate a positive test (+, >20 ng/ml aMMP-8 in the PISF) and one line indicates a negative test (−, <20 ng/ml aMMP-8 in the PISF) as pointed by the arrows on the right

of samples, writing, clinical diagnosis, patient treatment: Pirjo REFERENCES

The ability of quantitative, specific, and sensitive point-of-care/chair-side oral fluid immunotests for aMMP-8 to detect periodontal and periimplant diseases

Peri-implantitis diagnosis and prognosis using biomarkers in peri-implant crevicular fluid: A narrative review

Matrix metalloproteinase-8 as an Inflammatory and prevention biomarker in periodontal and periimplant diseases

Accuracy of single molecular biomarkers in gingival crevicular fluid for the diagnosis of periodontitis: A systematic review and meta-analysis

Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions

Biomarkers for periodontal diseases

Molecular tools for preventing and improving diagnosis of peri-implant diseases

Early pregnancy levels of gingival crevicular fluid matrix metalloproteinases-8 and -9 are associated with the severity of periodontitis and the development of gestational diabetes mellitus

Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression

Peri-implant health and disease. A systematic review of current epidemiology

Trends in dental implant use in the U.S., 1999-2016, and projections to 2026

Identification of polymorphonuclear leukocyte collagenase and gelatinase activities in mouthrinse samples: Correlation with periodontal disease activity in adult and juvenile periodontitis

An unexplored pharmacologic/diagnostic strategy for peri-implantitis: A protocol proposal

Prediabetes/diabetes screening strategy at the periodontal clinic

Prediabetes/diabetes can be screened at the dental office by a low-cost and fast chair-side/point-of-care aMMP-8 immunotest

Diagnostic Accuracy of oral fluids biomarker profile to determine the current and future status of periodontal and peri-implant diseases

Molecular forms and fragments of salivary MMP-8 in relation to periodontitis

Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline

Cross-sectional analysis of risk factors for subclinical periodontitis; active matrix metalloproteinase-8 as a potential indicator in initial periodontitis in adolescents

Peri-implant mucositis

Activated matrix metalloproteinase-8 in saliva as diagnostic test for periodontal disease? A case-control study

Local and systemic levels of aMMP-8 in gingivitis and stage 3 grade C periodontitis

Active matrix metalloproteinase-8 and interleukin-6 detect periodontal degeneration caused by radiotherapy of head and neck cancer: A pilot study

Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: Molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue

Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid

Laminin-5 gamma2-chain and collagenase-2 (MMP-8) in human peri-implant sulcular fluid

aMMP-8 point-of-care/chairside oral fluid technology as a rapid, non-invasive tool for periodontitis and peri-implantitis screening in a medical care setting

Association of MMP-8 with obesity, smoking and insulin resistance

Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: Role of active enzyme in human periodontitis

Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnostic value for chronic periodontitis

Gingival crevicular fluid matrix metalloproteinase-8 levels predict treatment outcome among smokers with chronic periodontitis

The utility of gingival crevicular fluid matrix metalloproteinase-8 response patterns in prediction of site-level clinical treatment outcome

Evaluation of a novel point-of-care test for active matrix metalloproteinase-8: Agreement between qualitative and quantitative measurements and relation to periodontal inflammation

Collagenases in different categories of peri-implant vertical bone loss

Assessment of a novel screening test for neutrophil collagenase activity in the diagnosis of periodontal diseases

Characteristics of early versus late implant failure: A retrospective study

Activation mechanisms of matrix metalloproteinases

Peri-implantitis and peri-implant mucositis case definitions in dental research: A systematic assessment

Treponema denticola chymotrypsin-like proteinase may contribute to orodigestive carcinogenesis through immunomodulation

Evaluation of active matrix metalloproteinase-8 (aMMP-8) chair-side test as a diagnostic biomarker in the staging of periodontal diseases

The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation

A systematic review of the survival and complication rates of implantsupported fixed dental prostheses (FDPs) after a mean observation period of at least 5 years

A point-of-care test of active matrix metalloproteinase-8 predicts triggering receptor expressed on myeloid cells-1 (TREM-1) levels in saliva

Point-of-care/chairside aMMP-8 analytics of periodontal diseases' activity and episodic progression

Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients

Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations

Activation of neutrophil collagenase in periodontitis

Relationship between TNF-α, MMP-8, and MMP-9 levels in gingival crevicular fluid and the subgingival microbiota in periodontal disease

Associations of chairside salivary aMMP-8 findings with periodontal parameters, potentially periodontal pathogenic bacteria and selected blood parameters in systemically healthy adults

Peri-implantitis

Active MMP-8 (aMMP-8) as a grading and staging biomarker in the periodontitis classification

Host-modulation therapy and chair-side diagnostics in the treatment of peri-implantitis

Cellular source, activation and inhibition of dental plaque collagenase

Analysis of matrix metalloproteinases, especially MMP-8, in gingival creviclular fluid, mouthrinse and saliva for monitoring periodontal diseases

Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods

Identification of proteases from periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast-type interstitial collagenases

Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase and gelatinase

Active matrix metalloproteinase-8 (aMMP-8) point-of-care test (POCT) in the COVID-19 pandemic

Activation of type IV procollagenases by human tumor-associated trypsin-2

Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation

Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate

Peri-implant sulcus fluid (PISF) matrix metalloproteinase (MMP)-8 levels in periimplantitis

Staging and grading of periodontitis: Framework and proposal of a new classification and case definition

A rapid, non-invasive tool for periodontitis screening in a medical care setting

Protein biomarkers and microbial profiles in peri-implantitis

Sulcus fluid bone marker levels and the outcome of surgical treatment of peri-implantitis

Characteristics of collagenase-2 from gingival crevicular fluid and peri-implant sulcular fluid in periodontitis and peri-implantitis patients: Pilot study

Active MMP-8 point-of-care (PoC)/chairside enzyme-test as an adjunctive tool for early and real-time diagnosis of peri-implantitis